To Prescribe or Not to Prescribe? Opioid Crisis Presents Ethical Dilemma
Deaths from prescription opioids like oxycodone and hydrocodone have more than quadrupled since 1999. So today, doctors trying to treat pain face a dilemma: to prescribe or not to prescribe? It’s a difficult question for health professionals who want to treat patients without sending them down the path to addiction. For example, at Birmingham’s Phoenix Clinic for homeless or formerly homeless veterans, Dr. Stefan Kertesz is examining Stacey Haley, who’s struggling with a brace and a very arthritic knee.
“So now we’re dealing with pain, right?” asks Kertesz. “And the problem is it’s not been easy to get this knee feeling well? So let’s talk about that.”
And they do talk, in detail, for almost a half an hour. The reasons the course of treatment isn’t an easy call are that Haley is working and doesn’t want to be sidelined by surgery, and there’s a potential red flag when it comes to prescribing opioids: he’s struggled with addiction in the past. But standard meds aren’t working. So Dr. Kertesz starts him on Tramadol.
“As long as they’re non-narcotics, I’m willing to try anything,” says Haley.
Kertesz replies, “I gotta break it to you, Tramadol is partly narcotic.”
But Haley is reassured because Kertesz explains that Tramadol is relatively low-potency. The main reason Kertesz is comfortable giving it to Haley, though, is that he sees Haley regularly.
“So we have to have a pretty careful conversation in the next few weeks about how it’s going,” Kertesz explains. “My expectation is we’re going to converse about whether it made you feel differently, whether you thought you were getting a buzz from it.”
It’s a dilemma doctors face every day: prescribe medicine that could relieve pain and keep patients functional, or withhold it because of potential addiction. Kertesz says taking time to really know patients is the only way to assess those risks. But in recent years, at least five states have limited the doses doctors can prescribe. And that worries him.
“Doctors are being told, ‘get the dose down, no matter what.’ And they’re saying, ‘I have no time, so I’ll just take everybody off, and who knows what happens to those people?’”
Patients who stop taking opioids often seek illegal drugs or suffer debilitating withdrawal.
“It’s usually a complicated situation,” says Kertesz. “That’s why a public policy solution that’s rooted on pill control alone will probably not work.”
At the same time, over-prescription has done tremendous harm. Several states, including Alabama, have more opiate prescriptions than people. And none of it happened overnight. David Juurlink, head of clinical pharmacology and toxicology at the University of Toronto, explains:
“One of the critical things that happened in the 1990s and early 2000s that helped doctors become more comfortable prescribing opioids for chronic pain was the assertion that addiction was rare. And we were told – I remember being taught myself – that less than one percent of people who were on opiates for chronic pain would become addicted.”
But he says it’s actually about five times that. Many trace the misconception to a widely cited one-paragraph letter in the New England Journal of Medicine in 1980, decades before its content could be easily checked online. The letter said the risk of addiction in a very specific, small patient population was low. But drugmakers, lobbyists, and some doctors overgeneralized that letter to quiet wider concerns about addiction. Juurlink just published a paper noting that, while the median number of similar letters’ citations was 11, that letter has been cited 608 times.
“There is a dark element to this, in what I’ll call the pain lobby,” Juurlink says. “There’s money at stake here. If doctors were to suddenly start using opioids less readily, and for shorter durations and at lower doses, the companies that have made tens of billions-with-a-B dollars would be unhappy.”
Juurlink is in something of a Twitter battle with Dr. Kertesz: Juurlink emphasizing the harms of over-prescription; Kertesz pointing out that government-imposed dose limits can cause harm too. But they actually agree on a lot. And Juurlink hasn’t stopped prescribing opioids altogether.
“It’s very tough,” he says. “My take is that they have a role … I tend to use them in people in whom other therapies haven’t worked or are too dangerous, but I am extremely judicious with the dosing.”
Juurlink and Kertesz also agree on this: because lives are at stake, there are no easy answers to the question of when to prescribe opioids.
NPR’s Stephen Bisaha contributed to this report.
Alabama Power seeks to delay rate hike for new gas plant amid outcry
The state’s largest utility has proposed delaying the rate increase from its purchase of a $622 million natural gas plant until 2028.
Former U.S. Sen. Doug Jones announces run for Alabama governor
Jones announced his campaign Monday afternoon, hours after filing campaign paperwork with the Secretary of State's Office. His gubernatorial bid could set up a rematch with U.S. Sen. Tommy Tuberville, the Republican who defeated Jones in 2020 and is now running for governor.
Scorching Saturdays: The rising heat threat inside football stadiums
Excessive heat and more frequent medical incidents in Southern college football stadiums could be a warning sign for universities across the country.
The Gulf States Newsroom is hiring an Audio Editor
The Gulf States Newsroom is hiring an Audio Editor to join our award-winning team covering important regional stories across Mississippi, Alabama and Louisiana.
Judge orders new Alabama Senate map after ruling found racial gerrymandering
U.S. District Judge Anna Manasco, appointed by President Donald Trump during his first term, issued the ruling Monday putting a new court-selected map in place for the 2026 and 2030 elections.
Construction on Meta’s largest data center brings 600% crash spike, chaos to rural Louisiana
An investigation from the Gulf States Newsroom found that trucks contracted to work at the Meta facility are causing delays and dangerous roads in Holly Ridge.


